All In Biotech

Drug Trial Radar · NCT07188805

A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Investigate the Efficacy, Safety, and PK/ PD of Finerenone, in Addition to Standard-of-care, in Pediatric Patients, 6 Months to < 18 Years of Age With Heart Failure (HF) and Left Ventricular Systolic Dysfunction (LVSD)

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 111 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

111

Planned (sponsor's estimate)

Start

Nov 19, 2025

Primary completion

Nov 30, 2029

Study completion Dec 30, 2029

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Sep 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 months, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for a better way to treat children who have heart failure with left ventricular systolic dysfunction (LVSD). Heart failure is a serious condition where the heart is unable to pump enough blood to meet the body's needs. This can lead to symptoms like shortness of breath, fatigue, and poor growth in children. The study treatment, finerenone (also called BAY94-8862), works by blocking a protein involved in inflammation, scarring, and thickening of the heart and blood vessels. This may help the heart to pump blood more effectively. This is the first study to explore its use specifically for children with heart failure and LVSD. The main purpose of this study is to learn if finerenone works to help the heart compared to placebo in children with heart failure and LVSD. For this, the researchers will collect and analyze data on the levels of a protein called NT-proBNP in the blood, which indicates heart stress, and monitor the safety of the treatment. The study will include children with heart failure and LVSD aged from 6 months to less than 18 years. The study participants will be randomly assigned to one of two treatment groups. Based on their group, they will receive either finerenone or a placebo for a duration of 3 months. A placebo looks like a treatment but does not have any medicine in it. Throughout the study, all participants will continue to receive their standard heart failure treatments. At the start of this study, the doctors will check each participant's medical history and current medications. If participants qualify for the treatment phase, they will undergo treatment for about 90 days. During this time, they will visit the study site at least 3 times. During these visits, the participants will: * have their blood pressure, heart rate, temperature, respiratory rate, height and weight measured * have their heart examined by electrocardiogram (ECG) and echocardiogram * have blood samples taken * have physical examinations * answer questions about their medication and whether they have any adverse events, or have their parents or guardians' answers An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments. After the initial three-month study, eligible participants will have the option to join a nine-month open-label extension study where all will receive finerenone. Participants who choose not to enroll in the extension will have a follow-up visit 30 days after their last treatment.

Conditions

  • Left Ventricular Systolic Dysfunction
  • Heart Failure (Pediatric)

Interventions

  • Finerenone (Kerendia, BAY94-8862)Drug

    Finerenone in different doses, treatment duration will be 90±3 days

  • PlaceboDrug

    Placebo to finerenone, treatment duration will be 90±3 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in NT-proBNP levelsTime frame: From baseline to Day 90±3

Locations

133 sites in 23 countries. Site status is shown where the registry gives one.

  • Children's Hospital Colorado - Anschutz Medical Campus - Cardiology

    Aurora, Colorado · Not yet recruiting

  • Nemours Children's Hospital - Delaware - Cardiology

    Wilmington, Delaware · Not yet recruiting

  • UF Health Shands Hospital - Pediatric Cardiology

    Gainesville, Florida · Not yet recruiting

  • Joe Dimaggio Children's Hospital - Cardiology

    Hollywood, Florida · Not yet recruiting

  • Emory University Hospital - Children's Healthcare of Atlanta Cardiology - Atlanta

    Atlanta, Georgia · Not yet recruiting

  • Riley Hospital For Children - Cardiology

    Indianapolis, Indiana · Not yet recruiting

  • Boston Children's Hospital - Main Campus - Cardiology

    Boston, Massachusetts · Not yet recruiting

  • C.S. Mott Children's Hospital - Cardiology

    Ann Arbor, Michigan · Not yet recruiting

  • Children's Mercy Hospital Kansas City - Cardiology

    Kansas City, Missouri · Not yet recruiting

  • Washington University - St. Louis Children's Hospital - Cardiology

    St Louis, Missouri · Not yet recruiting

  • Icahn School of Medicine at Mount Sinai - Pediatric Cardiology

    New York, New York · Not yet recruiting

  • Columbia University Irving Medical Center - Pediatric Cardiology

    New York, New York · Not yet recruiting

  • The Children's Hospital at Montefiore - Cardiology

    The Bronx, New York · Not yet recruiting

  • Cincinnati Children's Hospital Medical Center | Division of Nephrology and Hypertension

    Cincinnati, Ohio · Not yet recruiting

  • Cleveland Clinic Children's

    Cleveland, Ohio · Not yet recruiting

  • Nationwide Children's Hospital - Cardiology

    Columbus, Ohio · Not yet recruiting

  • Children's Hospital of Philadelphia - Cardiology

    Philadelphia, Pennsylvania · Not yet recruiting

  • UPMC Children's Hospital of Pittsburgh - Cardiology

    Pittsburgh, Pennsylvania · Not yet recruiting

  • MUSC Shawn Jenkins Children's Hospital - Cardiology

    North Charleston, South Carolina · Not yet recruiting

  • Children's Medical Center Dallas - Cardiology

    Dallas, Texas · Not yet recruiting

  • Texas Children's Hospital - Cardiology

    Houston, Texas · Not yet recruiting

  • Eccles Primary Children's Outpatient Services - Cardiology

    Salt Lake City, Utah · Not yet recruiting

  • Hospital Italiano de Buenos Aires

    Buenos Aires, Argentina · Not yet recruiting

  • Hospital General de Ninos Pedro de Elizalde | Nephrology Department

    Ciudad Autonoma de Buenos Aire, Argentina · Not yet recruiting

  • Consultorios Médicos Dr. Doreski

    Ciudad Autónoma de Buenos Aire, Argentina · Not yet recruiting

  • Sanatorio de la Cañada

    Córdoba, Argentina · Not yet recruiting

  • Centro Cardiovascular Salta (Torzav SRL)

    Salta, Argentina · Not yet recruiting

  • Hospital de Pediatría Juan P. Garrahan

    Buenos Aires, Buenos Aires, Argentina · Not yet recruiting

  • Hospital de Niños Sor María Ludovica

    La Plata, Buenos Aires, Argentina · Not yet recruiting

  • Instituto De Investigaciones Clinicas Zarate | Zarate, Argentina

    Zárate, Buenos Aires, Argentina · Recruiting

  • Hospital General de Ninos Ricardo Gutierrez | Cardiology Department

    Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina · Not yet recruiting

  • Consultorios Integrados Rosario | Instituto Medico de la Fundacion de Estudios Clinicos

    Rosario, Santa Fe Province, Argentina · Not yet recruiting

  • Medizinische Universität Wien - Klinik für Kinder- und Jugendheilkunde, Abteilung für Pädiatrische Kardiologie

    Vienna, State of Vienna, Austria · Not yet recruiting

  • Kepler Universitätsklinikum GmbH - Klinik für Kinderkardiologie

    Innsbruck, Upper Austria, Austria · Not yet recruiting

  • Cliniques Universitaires St-Luc (UCL) - Pediatric Cardiology

    Brussels, Belgium · Recruiting

  • UZ Antwerpen - Pediatric Cardiology

    Edegem, Belgium · Not yet recruiting

  • UZ Gent - Pediatric Cardiology

    Ghent, Belgium · Not yet recruiting

  • CHC MontLegia - Pediatric Cardiology

    Liège, Belgium · Not yet recruiting

  • UZ Leuven - Pediatric Cardiology

    Leuven, Flemish Brabant, Belgium · Not yet recruiting

  • Hospital de Clínicas da Universidade Federal de Uberlândia Empresa Brasileira de Serviços Hospitalares - EBSERH

    Uberlândia, Minas Gerais, Brazil · Withdrawn

Showing 40 of 133 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.